Is There a Role for FAPI PET in Urological Cancers?
Molecular Diagnosis & Therapy · 2024
DOI: 10.1007/s40291-024-00735-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Diagnosis & Therapy, 2024. Verfasst von Naima Ortolan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, University of Ferrara, Via Aldo Moro 8, 44124, Ferrara, Italy. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Urologic Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Università degli Studi di Ferrara.
Abstract (Originalsprache)
This work aims to investigate the utility of positron emission tomography/computed tomography (PET/CT) with fibroblast activation protein inhibitors (FAPI) in urological neoplasms, including prostate cancer, urothelial carcinoma, and renal cell carcinoma. Although the available data are very preliminary, FAPI PET showed potential for detecting primary prostate cancer with low prostate-specific membrane antigen expression, while prostate-specific membrane antigen PET/CT outperformed FAPI PET/CT in detecting biochemical recurrence. In urothelial carcinoma, FAPI PET/CT demonstrated increased detection rates compared with deoxy-2-[18F]fluoro-D-glucose PET/CT, in particular in small lymph node metastases, whose identification is still an unmet clinical need. Limited data are available for renal cell carcinoma. In conclusion, FAPI PET emerges as a promising imaging modality for urological neoplasms, in particular bladder cancer. Further research is warranted to establish its role in guiding therapeutic decisions and as a potential novel theranostic agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Translational Medicine, University of Ferrara, Via Aldo Moro 8, 44124, Ferrara, Italy.
- Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferarra, Italy.
- Department of Translational Medicine, University of Ferrara, Via Aldo Moro 8, 44124, Ferrara, Italy. rsulcu@unife.it.
- Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferarra, Italy. rsulcu@unife.it.
- Nuclear Medicine Unit, Department of Oncohematology, Fondazione PTV Policlinico Tor Vergata University Hospital, Rome, Italy.
- Department of Urology, IRCCS-Humanitas Research Hospital, Milan, Italy.
ORCID-Profile: Luca Urso
Förderung
- Università degli Studi di Ferrara
Zitieren
APA
Ortolan, N., Urso, L., Zamberlan, I., Filippi, L., Buffi, N. M., Cittanti, C., Uccelli, L., Bartolomei, M., & Evangelista, L. (2024). Is There a Role for FAPI PET in Urological Cancers?. Molecular Diagnosis & Therapy. https://doi.org/10.1007/s40291-024-00735-9
Vancouver
Ortolan N, Urso L, Zamberlan I, Filippi L, Buffi NM, Cittanti C, et al. Is There a Role for FAPI PET in Urological Cancers?. Molecular Diagnosis & Therapy. 2024. doi:10.1007/s40291-024-00735-9
BibTeX
@article{Ortolan2024,
author = {Ortolan, Naima and Urso, Luca and Zamberlan, Ilaria and Filippi, Luca and Buffi, Nicolò Maria and Cittanti, Corrado and Uccelli, Licia and Bartolomei, Mirco and Evangelista, Laura},
title = {Is There a Role for FAPI PET in Urological Cancers?},
journal = {Molecular Diagnosis & Therapy},
year = {2024},
doi = {10.1007/s40291-024-00735-9}
}
EUVIMED